CHEPLAPHARM Arzneimittel GmbH, a prominent player in the pharmaceutical industry, is headquartered in Greifswald, Germany. Founded in 1986, the company has established itself as a leader in the development, production, and distribution of high-quality generic and specialty pharmaceuticals. With a strong presence across Europe and expanding operations in various international markets, CHEPLAPHARM focuses on therapeutic areas such as oncology, cardiology, and neurology. The company is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to the evolving needs of healthcare providers and patients. Notable achievements include strategic partnerships and a robust pipeline of generics that enhance patient access to essential medications. CHEPLAPHARM's dedication to excellence positions it as a trusted name in the pharmaceutical landscape, continually striving to improve health outcomes worldwide.
How does CHEPLAPHARM Arzneimittel GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
CHEPLAPHARM Arzneimittel GmbH's score of 30 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, CHEPLAPHARM Arzneimittel GmbH reported total carbon emissions of approximately 146,900 kg CO2e, comprising 130,900 kg CO2e from Scope 1 and 16,000 kg CO2e from Scope 2 emissions. The Scope 1 emissions included about 33,600 kg CO2e from mobile combustion and 95,000 kg CO2e from stationary combustion. Notably, the company achieved a remarkable 92% reduction in Scope 2 emissions by transitioning its entire electricity consumption at German sites to renewable energy sources, significantly enhancing its environmental performance. In 2022, the company recorded total emissions of approximately 198,000 kg CO2e, with Scope 1 emissions from stationary combustion at 111,000 kg CO2e and Scope 2 emissions at 87,000 kg CO2e. The previous year, 2021, saw Scope 2 emissions peak at approximately 323,000 kg CO2e, indicating a positive trend in emission reductions. CHEPLAPHARM has demonstrated a commitment to sustainability through these significant reductions and the adoption of renewable energy, aligning with industry standards for climate action. The company has not disclosed any Scope 3 emissions data, focusing its current efforts on direct and indirect emissions from its operations.
Access structured emissions data, company-specific emission factors, and source documents
2021 | 2022 | |
---|---|---|
Scope 1 | - | 000,000 |
Scope 2 | 323,000 | 000,000 |
Scope 3 | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
CHEPLAPHARM Arzneimittel GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.